Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT1-HCCAA Phase IIa Biomarker Study
2017-004776-56Phase 2Terminated
- Sponsor
- Arctic Therapeutics
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acetylcysteine in Hereditary cystatin C amyloid angiopathy (HCCAA), sponsored by Arctic Therapeutics. Primary endpoints: Safety and tolerability of AT-1 and Pharmacokinetic parameters of AT-1. Started Sep 2018; status: terminated.
02
Drugs
acetylcysteine
03
Conditions
Hereditary cystatin C amyloid angiopathy (HCCAA)
Beyond the preview
Go deeper on 2017-004776-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004776-56.